# Cardiovascular Agents: Pulmonary Arterial Hypertension\*

## Length of Authorizations

365 Days

## Grandfathering\*

Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug previously but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.

## Prior Authorization Criteria

1.  Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
    -   Allergy to medications not requiring prior approval
    -   Contraindication to all medications not requiring prior approval
    -   History of unacceptable/toxic side effects to medications not requiring prior approval
2.  Patients who have class 3 or 4 symptoms defined by the NYHA Functional Class for Pulmonary Hypertension may be approved for inhalation or intravenous agents
3.  Riociguat (Adempas) may be approved for patients with persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) who have had surgical treatment or have inoperable CTEPH.
4.  Has the patient failed a therapeutic trial of at least **30 days** with at least two medications, one of which is a Phosphodiesterase-5 Inhibitor, not requiring prior approval?

AR - Sildenafil oral solution: a PA is required for patients over 6 years old

## Formulary

Cardiovascular Agents: Pulmonary Arterial Hypertension

| PREFERRED             | NON-PREFERRED |
|-----------------------|---------------|
| Ambrisentan PA        | Adempas       |
| Sildenafil PA         | Bosentan      |
| Sildenafil Susp AR PA | Epoprostenol  |
| Tadalafil PA          | Opsumit       |
| Tracleer BvG PA       | Tracleer Susp |
|                       | Treprostinil  |
|                       | Tyvaso        |
|                       | Uptravi       |
|                       | Ventavis      |

### Link to Criteria

[Cardiovascular Agents: Pulmonary Arterial Hypertension](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220415_UPDL_Criteria_FINAL_.pdf#page=20)
